Cutter Capital Management, LP has filed its 13F form on August 14, 2024 for Q2 2024 where it was disclosed a total value porftolio of $331 Billion distributed in 27 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Biomarin Pharmaceutical Inc with a value of $22.5B, Merck & Co., Inc. with a value of $21.7B, Gilead Sciences, Inc. with a value of $20.1B, Amgen Inc with a value of $20.1B, and Royalty Pharma PLC with a value of $18.3B.

Examining the 13F form we can see an increase of $69.8B in the current position value, from $262B to 331B.

Cutter Capital Management, LP is based out at New York, NY

Below you can find more details about Cutter Capital Management, LP portfolio as well as his latest detailed transactions.

Portfolio value $331 Billion
Healthcare: $290 Billion
Basic Materials: $8.48 Billion

Stock Holdings Table Market Cap. of $300 Millions to $2 Billions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 27
  • Current Value $331 Billion
  • Prior Value $262 Billion
  • Filing
  • Period Q2 2024
  • Filing Date August 14, 2024
  • Form Type 13F-HR
  • Activity in Q2 2024
  • New Purchases 12 stocks
  • Additional Purchases 9 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 5 stocks
Track This Portfolio

Track Cutter Capital Management, LP Portfolio

Follow Cutter Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutter Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutter Capital Management, LP with notifications on news.